BOOK REVIEWS: Treatment of Multiple Sclerosis Trial Design, Results and Future Perspectives

Francis, DA
January 1993
Journal of Neurology, Neurosurgery & Psychiatry;Jan1993, Vol. 56 Issue 1, p120
Book Review
No abstract available.


Related Articles

  • Book Reviews. Dollfus, P.; Bone, Ian; Pentland, Brian // Spinal Cord;Jan1998, Vol. 36 Issue 1, p73 

    Reviews several non-fiction books related to the management of spinal cord diseases. 'Spinal Cord Diseases: Basic Science, Diagnosis, and Management,' edited by E. Critchley and A. Eisen; 'Multiple Sclerosis: Advances in Clinical Trial Design, Treatment and Future Perspectives,' edited by D.E....

  • ANNOTATIONS.  // IRB: Ethics & Human Research;Nov/Dec2015, Vol. 37 Issue 6, p8 

    Reviews of the articles "Patient perspectives on physician conflict of interest in industry sponsored clinical trials for multiple sclerosis therapeutics" in the "Multiple Sclerosis Journal" and "Promoting informed decision making for comparative effectiveness randomized trials" are presented.

  • Cannabis MS benefits 'subjective'  // Pulse;11/10/2003, Vol. 63 Issue 45, p7 

    Reports on the results of the randomized trial on cannabinoids as a treatment for multiple sclerosis in Great Britain. Mechanism underlying the treatment's action; Capacity of the treatment to improve mobility and pain control in multiple sclerosis; Safety profile in terms of general adverse events.

  • Natalizumab treatment reduces fatigue in multiple sclerosis. Results from the TYNERGY trial; a study in the real life setting.  // Current Medical Literature: Multiple Sclerosis;2013, Vol. 5 Issue 2, p46 

    A review of the article "Natalizumab treatment reduces fatigue in multiple sclerosis. Results from the TYNERGY trial; a study in the real life setting," by A. Svenningsson and colleagues, which appeared in the journal "PloS One" in 2013, is presented.

  • Multiple sclerosis drug approved.  // Executive Health's Good Health Report;Feb97, Vol. 33 Issue 5, p8 

    Focuses on the US Food and Drug Administration's approval of Copaxone for the treatment of relapsing-remitting multiple sclerosis (MS). Features of the drug; Results of clinical trials of the drug; Difference to previous classes of multiple sclerosis drugs.

  • Use of Intravenous Immunoglobulin in Multiple Sclerosis. Achiron, A.; Barak, Y.; Sarova-Pinhas, I. // BioDrugs;1998, Vol. 9 Issue 6, p465 

    Intravenous immunoglobulin (IVIg) pooled from healthy human volunteers has a role in several immunomodulating mechanisms which may affect the pathogenesis of multiple sclerosis. Modulation of the disease course by IVIg is achieved both by limiting the inflammatory process and by enhancing...

  • Role of oral teriflunomide in the management of multiple sclerosis. Tanasescu, Radu; Evangelou, Nikos; Constantinescu, Cris S. // Neuropsychiatric Disease & Treatment;2013, Vol. 9, p539 

    The landscape of the treatment of relapsing-remitting multiple sclerosis is changing fast. Several oral treatments have shown benefit and generate much interest because of the convenience of their administration. Two oral compounds, fingolimod and teriflunomide, have been approved in...

  • Acorda completes enrolment for Phase III MS trial.  // PharmaWatch: CNS;Jan2008, Vol. 7 Issue 1, p6 

    The article reports that biotechnology company Acorda Therapeutics Inc. has completed enrollment for its Phase III clinical trial of Fampridine-SR for the treatment of multiple sclerosis. The trial is designed to evaluate the safety and effectiveness of Fampridine-SR in multiple sclerosis....

  • Promising results in early Antegren trial.  // Inside MS;Winter2002, Vol. 20 Issue 1, p36 

    Reports on the result of an early double-blind clinical trial of Antegren as announced at the 7th Congress of the European Committee on Treatment and Research in Multiple Sclerosis on September 15, 2001. Number of multiple sclerosis patients who participated in the trial; Effects of Antegren;...

  • Treatment of multiple sclerosis: current concepts and future perspectives. Buck, Dorothea; Hemmer, Bernhard // Journal of Neurology;Oct2011, Vol. 258 Issue 10, p1747 

    Currently, several disease-modifying therapies for the treatment of multiple sclerosis are established and more are likely to be introduced. These treatment options differ with respect to their application profile, mechanism of action, efficacy, safety, and tolerance. Here, we review current...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics